Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Dupilumab in Patients With Persistent Asthma

Next Previous
Trial Profile

A Randomized, Double Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Dupilumab in Patients With Persistent Asthma

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 24 Feb 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dupilumab (Primary) ; Corticosteroid; Levosalbutamol; Salbutamol
  • Indications Asthma
  • Focus Registrational; Therapeutic Use
  • Acronyms Liberty Asthma Quest; QUEST
  • Sponsors Sanofi

Most Recent Events

  • 26 Apr 2024 According to a Sanofi media release, post-hoc analysis data from this study will be presented at the American Thoracic Society (ATS) International Conference taking place from May 17-22 in San Diego
  • 25 Nov 2023 Results of post-hoc analysis from NCT02134028 and NCT02414854; investigating long-term dupilumab efficacy in reducing exacerbations across yearly seasons in patients with type 2 inflammatory asthma with and without clinical evidence of allergic asthma, published in the Annals of Allergy, Asthma and Immunology
  • 01 Oct 2023 Results of post-hoc analysis of 2 studies (LIBERTY ASTHMA QUEST trial (NCT02414854) and TRAVERSE open-label extension (NCT02134028) ) assessing dupilumab efficacy, published in the Clinical and Experimental Allergy.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top